Proposal to list medical devices supplied by Jackson Allison and Getz Healthcare
PHARMAC is seeking feedback on a proposal to list medical devices supplied by Jackson Allison Medical and Surgical Limited and Getz Healthcare Limited.
What we’re proposing
Jackson Allison Medical and Surgical Limited (“Jackson Allison“) and Getz Healthcare Limited (“Getz Healthcare”) in Part III of Section H of the Pharmaceutical Schedule from 1 May 2021 through a non-exclusive provisional agreement.
We propose to list medical devices in the following categories:
- non-dedicated & consumable infusion devices;
- non-dedicated feeding devices; and
- infusion equipment and associated devices
- infusion equipment and associated devices; and
- peritoneal dialysis equipment and consumables
Consultation closes at 4pm Wednesday 24 March 2021 and feedback can be emailed to firstname.lastname@example.org.
What would the effect be?
From 1 May 2021, non-dedicated & consumable infusion devices, infusion equipment and associated devices and non-dedicated feeding devices supplied by Jackson Allison and infusion equipment and associated devices and peritoneal dialysis equipment and consumables supplied by Getz Healthcare would be listed under a proposed national agreement for all DHB hospitals to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).
The Agreement would not be for sole supply and DHBs could continue to be able to purchase other suppliers’ brands of products in these categories of devices.
The Agreement would supersede any existing DHB contracts with Jackson Allsion and Getz Healthcare for the products included in the Agreement. Any product listed in the Agreement and purchased by a DHB would be in accordance with the terms and conditions, including price, stated in the Agreement effective from the date of listing on the Pharmaceutical Schedule.
Jackson Allison and Getz Healthcare would provide appropriate educational services that would be tailored to the individual needs of DHBs, in formats and at times as required by DHBs.
Pricing for the devices in this Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by PHARMAC.
Who we think will be interested
- DHB clinical staff in a range of different clinical settings inluding:
- Procurement officers and supply chain personnel
- Clinical engineers and maintenance services
- ICU, emergency, and critical care staff
- Perioperative care staff
- Nurses (both inpatient and community based)
- Suppliers and wholesalers
About the medical devices
Infusion devices are medical devices used, or associated with devices used, in the infusion of fluids such as medications, intravenous solutions (such as saline, glucose, and electrolyte solutions), blood, total parenteral nutrition (TPN) solutions into the body. This includes medical devices used in intravenous therapy as well as other infusion therapies.
PHARMAC’s infusion devices category includes:
- non-dedicated and consumable infusion devices not associated with infusion equipment; and
- infusion equipment and associated devices.
Feeding devices are medical devices used to deliver nutrition and hydration into the body through the gastrointestinal tract (enteral nutrition). Devices that supply nutrition via the circulatory system (parenteral nutrition) are contracted under the Infusion devices category.
Providing nutrition to patients who cannot consume adequate food and/or fluids orally is important to optimise healing, reduce recovery times, and lower complication rates. Feeding devices are used by patients with a wide variety of clinical conditions and across both acute and community-based settings.
PHARMAC’s feeding devices category includes:
- Feeding equipment and associated devices
- Non-dedicated feeding devices
Peritoneal dialysis is a type of renal dialysis treatment which uses the peritoneum in a patient’s abdomen as the membrane for fluid exchange. The dialysis fluid is introduced into the patient’s peritoneum and then removed with the waste products absorbed.
This can occur whilst a patient sleeps (automated peritoneal dialysis, APD) or during the day as a patient moves around (Continuous Ambulatory Peritoneal Dialysis - CAPD). The medical devices in this category include the dialysis equipment, fluids that are introduced and the associated consumables such as catheters and preparatory products.
Why we’re proposing this
In 2018 PHARMAC issued Requests for Proposals for:
- supply of infusion devices (including non-dedicated and consumable infusion devices and infusion equipment and associated devices); and
- supply of feeding devices and/or special foods delivered enterally or orally.
In September 2020, PHARMAC released a Registration of Interest (“ROI”) as an opportunity for suppliers to have their peritoneal dialysis equipment and consumables considered for listing on the Pharmaceutical Schedule.
The RFPs and ROI were for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers who responded to the RFPs and ROI to seek provisional agreements. This proposal is the latest to arise from this process. and we expect to consult on further provisional agreements with suppliers of Infusion, Feeding, and Peritoneal Dialysis Devices throughout 2021.
Details about our proposal
PHARMAC has entered into a provisional agreement with Jackson Allison for the supply of non-dedicated & consumable infusion devices, infusion equipment and associated devices, and non-dedicated feeding devices, and with Getz Healthcare for peritoneal dialysis equipment and consumables. The proposal would result in Pharmaceutical Schedule listings for:
Number of Products
non-dedicated & consumable infusion devices
DeRoyal Industries, Intra, Fairmont, Nipro, Smiths UK, VBM
non-dedicated feeding devices
infusion equipment and associated devices
peritoneal dialysis equipment and consumables
infusion equipment and associated devices
Belmont Rapid Infusor, Belmont Buddy Lite
Further information, including pricing and contractual details, has been provided to DHB procurement personnel. Clinicians interested in further detail on what this change means for their DHB should engage with their procurement teams.
To provide feedback
Send us an email: email@example.com by 4pm Wednesday 24 March 2021.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Your feedback may be shared
Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.
We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.